Limits...
Expression of parvin-beta is a prognostic factor for patients with urothelial cell carcinoma of the upper urinary tract.

Wu CF, Ng KF, Chen CS, Chang PL, Chuang CK, Weng WH, Liao SK, Pang ST - Br. J. Cancer (2010)

Bottom Line: Functional assays indicated that overexpression of ParvB in an urothelial cancer cell line resulted in decreased cell growth rate and ability to migrate.In contrast, knockdown of ParvB expression increased cell migration ability.Downregulation of ParvB expression significantly increased urothelial cancer cell growth and migration.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Division of Urology, Chia-Yi Chang Gung Memorial Hospital, Chia-Yi, Taiwan.

ABSTRACT

Background: Parvin-beta (ParvB), a potential tumour suppressor gene, is a focal adhesion protein. We evaluated the role of ParvB in the upper urinary tract urothelial cell carcinoma (UUT-UC).

Methods: ParvB mRNA and proteins levels in UUT-UC tissue were investigated by quantitative real-time polymerase chain reaction and western blot analysis, respectively. In addition, the expression of ParvB in tissues from patients with UUT-UC at different stages was evaluated by immunohistochemistry. Furthermore, biological functions of ParvB in urothelial cancer cells were investigated using a doxycycline-inducible overexpression system and siRNA.

Results: Western blot and mRNA analysis showed downregulation of ParvB expression in frozen UUT-UC tissue. Immunohistochemistry revealed high staining intensity of ParvB in normal urothelium, which decreased markedly at advanced stages of UUT-UC (P=0.0000). Moreover, ParvB was an independent prognostic indicator for disease-specific survival of patients with UUT-UC. Functional assays indicated that overexpression of ParvB in an urothelial cancer cell line resulted in decreased cell growth rate and ability to migrate. In contrast, knockdown of ParvB expression increased cell migration ability.

Conclusions: Downregulation of ParvB expression significantly increased urothelial cancer cell growth and migration. Downexpression of ParvB level in UUT-UC correlated with tumour stage, and was an independent unfavourable prognostic factor for disease-specific survival of patients with UUT-UC.

Show MeSH

Related in: MedlinePlus

The study of ParvB mRNA (A) and protein level (B) in human upper urinary tract urothelial carcinoma in paired samples indicated that ParvB was downregulated in tumour sample as compared with normal tissue. Error bars indicate standard deviation for triplicate experiment data (□: normal urothelium; ▪: tumour).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2966628&req=5

fig1: The study of ParvB mRNA (A) and protein level (B) in human upper urinary tract urothelial carcinoma in paired samples indicated that ParvB was downregulated in tumour sample as compared with normal tissue. Error bars indicate standard deviation for triplicate experiment data (□: normal urothelium; ▪: tumour).

Mentions: We performed quantitative RT–PCR on RNA isolated from 19 patient-matched UUT-UC and normal urothelium tissues. Parvin-β mRNA expression was downregulated in all tumours (Figure 1A). As ParvB mRNA expression was downregulated in UUT-UC, we examined ParvB protein levels. Parvin-β protein levels from 10 patient-matched normal urothelium and tumour tissues were assessed. Downregulation of ParvB protein levels were detected in seven of 10 tumours (Figure 1B). Furthermore, ParvB protein levels were decreased by >50% in four of seven tumours. Our results show that ParvB is downregulated in UC tumours at both mRNA and protein levels.


Expression of parvin-beta is a prognostic factor for patients with urothelial cell carcinoma of the upper urinary tract.

Wu CF, Ng KF, Chen CS, Chang PL, Chuang CK, Weng WH, Liao SK, Pang ST - Br. J. Cancer (2010)

The study of ParvB mRNA (A) and protein level (B) in human upper urinary tract urothelial carcinoma in paired samples indicated that ParvB was downregulated in tumour sample as compared with normal tissue. Error bars indicate standard deviation for triplicate experiment data (□: normal urothelium; ▪: tumour).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2966628&req=5

fig1: The study of ParvB mRNA (A) and protein level (B) in human upper urinary tract urothelial carcinoma in paired samples indicated that ParvB was downregulated in tumour sample as compared with normal tissue. Error bars indicate standard deviation for triplicate experiment data (□: normal urothelium; ▪: tumour).
Mentions: We performed quantitative RT–PCR on RNA isolated from 19 patient-matched UUT-UC and normal urothelium tissues. Parvin-β mRNA expression was downregulated in all tumours (Figure 1A). As ParvB mRNA expression was downregulated in UUT-UC, we examined ParvB protein levels. Parvin-β protein levels from 10 patient-matched normal urothelium and tumour tissues were assessed. Downregulation of ParvB protein levels were detected in seven of 10 tumours (Figure 1B). Furthermore, ParvB protein levels were decreased by >50% in four of seven tumours. Our results show that ParvB is downregulated in UC tumours at both mRNA and protein levels.

Bottom Line: Functional assays indicated that overexpression of ParvB in an urothelial cancer cell line resulted in decreased cell growth rate and ability to migrate.In contrast, knockdown of ParvB expression increased cell migration ability.Downregulation of ParvB expression significantly increased urothelial cancer cell growth and migration.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Division of Urology, Chia-Yi Chang Gung Memorial Hospital, Chia-Yi, Taiwan.

ABSTRACT

Background: Parvin-beta (ParvB), a potential tumour suppressor gene, is a focal adhesion protein. We evaluated the role of ParvB in the upper urinary tract urothelial cell carcinoma (UUT-UC).

Methods: ParvB mRNA and proteins levels in UUT-UC tissue were investigated by quantitative real-time polymerase chain reaction and western blot analysis, respectively. In addition, the expression of ParvB in tissues from patients with UUT-UC at different stages was evaluated by immunohistochemistry. Furthermore, biological functions of ParvB in urothelial cancer cells were investigated using a doxycycline-inducible overexpression system and siRNA.

Results: Western blot and mRNA analysis showed downregulation of ParvB expression in frozen UUT-UC tissue. Immunohistochemistry revealed high staining intensity of ParvB in normal urothelium, which decreased markedly at advanced stages of UUT-UC (P=0.0000). Moreover, ParvB was an independent prognostic indicator for disease-specific survival of patients with UUT-UC. Functional assays indicated that overexpression of ParvB in an urothelial cancer cell line resulted in decreased cell growth rate and ability to migrate. In contrast, knockdown of ParvB expression increased cell migration ability.

Conclusions: Downregulation of ParvB expression significantly increased urothelial cancer cell growth and migration. Downexpression of ParvB level in UUT-UC correlated with tumour stage, and was an independent unfavourable prognostic factor for disease-specific survival of patients with UUT-UC.

Show MeSH
Related in: MedlinePlus